NAS:CBPO (China) Also Trade In: Germany Mexico UK

China Biologic Products Holdings Inc $ 118.70 0.7 (0.59%)

On watch
Volume:
47,531
Avg Vol (1m):
134,688
Market Cap $:
4.59 Bil
Enterprise Value $:
3.58 Bil
PE Ratio:
33.08
PB Ratio:
2.43
Warning! GuruFocus has detected 2 Severe warning signs with CBPO. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for China Biologic Products Holdings Inc () from 2001 to Apr 19 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. China Biologic Products stock (CBPO) PE ratio as of Apr 19 2021 is 33.08. More Details

China Biologic Products PE Ratio (TTM) Chart

EMBED

China Biologic Products PE Ratio (TTM) Historical Data

Total 1210
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
China Biologic Products PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-04-1933.2 2021-02-1533.2
2021-04-1633.0 2021-02-1233.2
2021-04-1533.0 2021-02-1133.1
2021-04-1433.0 2021-02-1033.2
2021-04-1333.0 2021-02-0933.1
2021-04-1233.1 2021-02-0833.1
2021-04-0933.0 2021-02-0533.0
2021-04-0833.0 2021-02-0433.0
2021-04-0733.0 2021-02-0333.0
2021-04-0632.9 2021-02-0233.0
2021-04-0532.9 2021-02-0133.1
2021-04-0233.0 2021-01-2932.9
2021-04-0133.0 2021-01-2833.0
2021-03-3133.1 2021-01-2733.0
2021-03-3033.1 2021-01-2633.1
2021-03-2933.1 2021-01-2533.1
2021-03-2633.0 2021-01-2233.0
2021-03-2533.0 2021-01-2133.1
2021-03-2433.0 2021-01-2033.1
2021-03-2332.9 2021-01-1933.1
2021-03-2232.8 2021-01-1533.1
2021-03-1932.9 2021-01-1433.0
2021-03-1832.8 2021-01-1332.9
2021-03-1732.7 2021-01-1233.0
2021-03-1632.7 2021-01-1133.0
2021-03-1532.7 2021-01-0833.1
2021-03-1232.8 2021-01-0733.0
2021-03-1132.7 2021-01-0633.0
2021-03-1032.7 2021-01-0533.0
2021-03-0932.7 2021-01-0433.0
2021-03-0832.8 2020-12-3133.0
2021-03-0532.9 2020-12-3032.9
2021-03-0433.0 2020-12-2933.0
2021-03-0333.0 2020-12-2833.0
2021-03-0232.9 2020-12-2432.9
2021-03-0133.0 2020-12-2332.9
2021-02-2633.4 2020-12-2233.0
2021-02-2533.4 2020-12-2133.0
2021-02-2433.5 2020-12-1833.1
2021-02-2333.5 2020-12-1733.0
2021-02-2233.5 2020-12-1633.0
2021-02-1933.4 2020-12-1533.0
2021-02-1833.4 2020-12-1433.0
2021-02-1733.5 2020-12-1133.1
2021-02-1633.4 2020-12-1033.1

China Biologic Products PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325414 NAICS : 2836
Address
19 Chaoyang Park Road, 18th Floor, Jialong International Building, Chaoyang District, Beijing, CHN, 100125
China Biologic Products Holdings Inc is a biopharmaceutical company principally engaged in the research, development, manufacturing and sales of human plasma-based products in China. The company operates its business through two majority owned subsidiaries, Shandong Taibang and Guizhou Taibang. China Biologic's product pipeline includes a variety of dosages across multiple product categories. Its principal products are human albumin and immunoglobulin for intravenous injection. All of the company's products are prescription medicines administered in the form of injections. China Biologic's sales model focuses on direct sales to hospitals and inoculation centers and is complemented by distributor sales.